Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs.
In this fourth annual Respiratory e-book, learn more about Porex and Nemera and their contributions to inhalation drug delivery and device design.
This whitepaper delves into the numerous benefits of long-acting drug delivery systems, including their ability to harness highly potent APIs, streamline development and intellectual property protection, and provide consistent drug release over extended periods.
Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to….
PLATFORM DEVICE – Alina: Shining the “Light” on the Benefits of a Platform Approach to Treating Chronic Conditions
Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.
Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.
FORMULATION FORUM – PLGA – A Versatile Copolymer for Design & Development of Nanoparticles for Drug Delivery
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the chemistry, properties, applications, and regulatory aspects of PLGA, and the future trends in the industry, especially those requiring the development of long-acting injectables for the treatment of a variety of rare diseases and for life cycle management.
Chris Preti, President of Jubilant HollisterStier, discusses how the CMO is handling increased demand for sterile fill finish and how expertise makes a difference to customer relationships and finished product quality.
Ross Errington explores the latest developments in the pMDI segment and explains the steps pharmaceutical companies need to take to ensure their pMDI drug products are ready to thrive in a very different market environment.
Darren Hieber discusses his company’s progress after his first year as Sr. Vice President of Corporate Development and Partnerships at Lifecore Biomedical.
EXCLUSIVE ONLINE CONTENT
Biodexa Enters Agreements to Acquire Exclusive Worldwide License to a Phase 2 Ready Asset for Type 1 Diabetes
Biodexa Pharmaceuticals PLC recently announced it has entered into an agreement for the assignment of Adhera Therapeutics, Inc.’s rights to tolimidone (formerly coded MLR-1023) under an exclusive,….
Hovione Acquires ExtremoChem & Its Portfolio of Proprietary Sugars to Support Customers With Stabilization & Delivery of Biopharmaceuticals
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, has recently announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on….
In Cayman Currents Issue 36, Cayman Chemical showcases the ongoing discoveries and innovation advancing lipid nanoparticles (LNPs) to the forefront of modern medicine and highlights tools available to support LNP research.
Acumen Pharmaceuticals & Halozyme Enter Global Collaboration & License Agreement to Develop Subcutaneous Formulation of ACU193 With ENHANZE Technology
Acumen Pharmaceuticals, Inc. recently announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc. to provide Acumen access to Halozyme’s ENHANZE drug delivery technology, based on….
Cambrex recently completed the sale of its Drug Product Business Unit to Wilmington, DE- based Noramco. Cambrex’s Drug Product business provides….
MARKET NEWS & TRENDS
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
WEBINAR – Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation
In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….
The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing. Since these devices….
In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.
WHITEPAPER – Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance
To gain insights into advanced copolymer characterization techniques and their impact on drug release in biomedical products, we invite you to explore the latest Corbion white paper…..
WHITEPAPER – The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation
This white paper evaluates the viscosity-reducing capacities of excipients and excipient combinations…..
WHITEPAPER – Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination
This paper covers the benefits of the LBF and capsules combination in dosage form developments, an efficient technology platform to bring efficient and differentiated products to the market.
In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and….
Going forward, sponsors developing ophthalmic products formulated for delivery as eye drops must be prepared to pursue development programs that address the regulatory requirements for drug-device combination products. Partnering with a contract manufacturing organization (CMO) that has experience bringing such products to market is essential…..